Qi Shuya, Liu Lixing
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
National Cancer Center/National Clinical Research Center for Cancer/Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang, 065001, China.
Heliyon. 2024 Jun 18;10(12):e33074. doi: 10.1016/j.heliyon.2024.e33074. eCollection 2024 Jun 30.
Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is an effective treatment for chemotherapy-induced neutropenia. However, it can also induce various adverse effects, including fever, bone pain, and other discomforts arising from the abnormal proliferation of blood cells. This study presents an analysis of a case involving a middle-aged patient with small cell lung cancer who exhibited transiently low blood glucose levels without experiencing any symptoms of hypoglycemia following PEG-rhG-CSF treatment. After thorough evaluation by clinicians and pharmacists, the condition was diagnosed as pseudohyperglycemia, a phenomenon distinct from true hyperglycemia. The article provides a pharmaceutical perspective on the contributing factors, mechanisms, and management strategies for pseudohypoglycemia, offering valuable insights for clinical practice.
聚乙二醇化重组人粒细胞集落刺激因子（PEG-rhG-CSF）是治疗化疗引起的中性粒细胞减少症的有效药物。然而，它也会引发各种不良反应，包括发热、骨痛以及血细胞异常增殖引起的其他不适。本研究分析了一例中年小细胞肺癌患者的病例，该患者在接受PEG-rhG-CSF治疗后出现短暂低血糖水平，但未出现任何低血糖症状。经临床医生和药剂师全面评估后，该病症被诊断为假性低血糖症，这是一种与真性高血糖症不同的现象。本文从药学角度对假性低血糖症的促成因素、机制及管理策略进行了探讨，为临床实践提供了有价值的见解。
